Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026Business Wire • 03/17/26
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's CancersBusiness Wire • 03/17/26
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?Zacks Investment Research • 03/11/26
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 03/04/26
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026Business Wire • 02/18/26
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary ResultsZacks Investment Research • 02/05/26
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven CancersBusiness Wire • 02/04/26
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLCSeeking Alpha • 12/30/25
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung CancerBusiness Wire • 12/29/25
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of GrowthBusiness Wire • 12/15/25
Verastem Oncology to Present at the 8th Annual Evercore Healthcare ConferenceBusiness Wire • 11/25/25
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 11/14/25
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 11/04/25
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid TumorsBusiness Wire • 10/23/25
Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 10/23/25
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025Business Wire • 10/23/25